Bessemer Group
CLVS

Bessemer Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Bessemer Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38
Closed -$1K – 1490
2016
Q1 		$1K Buy
+38
New +$804 ﹤0.01% 1441
2013
Q3 		– Sell
-1,350
Closed -$90K – 1405
2013
Q2 		$90K Buy
+1,350
New +$60.7K ﹤0.01% 666

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PointState Capital
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bessemer Group's CLVS Position: Q2 2016 in Review

Bessemer Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 38 shares — an estimated $1K sold.

Bessemer Group first reported a position in CLVS in Q2 2013 and held it in 2 quarters. The position peaked at $90K in Q2 2013. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

  • Bessemer Group reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 38 Clovis Oncology, Inc. shares in Q2 2016, an estimated $1K.
  • Bessemer Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 2 quarters.
  • Bessemer Group's Clovis Oncology, Inc. position peaked at $90K in Q2 2013.
  • 122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.